Skip to content

The effect of bromocriptine on endometrioma size

The evaluation of therapeutic effect of dopamine agonist (bromocriptine) on endometrioma size

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140802018655N6
Enrollment
60
Registered
2021-01-06
Start date
2018-12-22
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrioma. Endometriosis of ovary

Interventions

Intervention 1: Intervention group: Received medroxyprogesterone 20 mg with Bromocriptine 1/25 mg twice daily for at least 3 months. Intervention 2: Control group: Received medroxyprogesterone 20 mg

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: A definitive diagnosis of endometrioma

Exclusion criteria

Exclusion criteria: patients with hyperprolactinemia People with coagulation disorders who have contraindications to medroxyprogesterone

Design outcomes

Primary

MeasureTime frame
Endometrioma size. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: Ultrasonography.;Pain pelvic. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: VAS test.

Secondary

MeasureTime frame
Dysmenorrhea. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: VAS test.;Dyspareunia. Timepoint: Before transplantation and at the end of 3 months. Method of measurement: VAS test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTahereh Poordast

Shiraz University of Medical Sciences

ta.poordast@yahoo.com+98 71 3230 4596

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026